Health Trials

Clinical trials

6

Search and review clinical trials. Use filters to narrow results by trial status, phase, treatment, biological sex and sponsor.

Condition / disease
Location
Status: Not yet recruiting

A Phase I Study of YK012 in Primary Membranous Nephropathy

The goal of this clinical trial is to evaluate the safety, tolerability, pharmacokinetics(PK), pharmacodynamics (PD), immunogenicity, and preliminary efficacy of YK012 in participants with primary membranous nephropathy (pMN).

Participants needed: 66
Trial details
Phase: Phase 1Age: 18-80Biological sex: AllType: InterventionalSponsor: Excyte Biopharma LtdUpdated: Feb 5, 2026
Eligibility criteria

Age 18-80 (inclusive), both gender. [+6]

Diagnosed with secondary membranous nephropathy. [+17]

Read more
Status: Recruiting

Study of YK012 in Moderate to Severe Systemic Lupus Erythematosus

The goal of this clinical trial is to evaluate the safety, tolerability, pharmacokinetics (PK), pharmacodynamics (PD), and preliminary efficacy of YK012 in participants with Moderate to Severe Systemic Lupus Erythematosus (SLE).

Participants needed: 189
Trial details
Phase: Phase 1, Phase 2Age: 18-75Biological sex: AllType: InterventionalSponsor: Excyte Biopharma LtdUpdated: Feb 5, 2026Locations: 1
Eligibility criteria

Aged 18 to 75 years (inclusive) at screening, regardless of sex [+5]

Known allergy to monoclonal antibodies or exogenous human immunoglobulins, or hy... [+24]

Read more
Status: Recruiting

A Study of YKST02 in Participants With Relapsed or Refractory Multiple Myeloma

This study aims to provide a basis for further clinical development of YKST02. YKST02 is a study medicine that targets multiple myeloma and activates the human body to fight against this disease.

Participants needed: 70
Trial details
Phase: Phase 1Age: 18-75Biological sex: AllType: InterventionalSponsor: Excyte Biopharma LtdUpdated: Feb 5, 2026Locations: 12
Eligibility criteria

Participants or their legally acceptable representative must sign an ICF indicat... [+11]

Plasma cell leukemia (>2.0×10^9/L plasma cells by standard differential), Walden... [+31]

Read more
Status: Recruiting

Study of YK012 in B-cell Acute Lymphoblastic Leukemia

The purpose of this study is to assess the safety, tolerability, pharmacokinetics and preliminary anti-tumor activity of YK012 administered as monotherapy in participants with B-cell acute lymphoblastic leukemia (B-ALL).

Participants needed: 46
Trial details
Phase: Phase 1, Phase 2Age: 18-75Biological sex: AllType: InterventionalSponsor: Excyte Biopharma LtdUpdated: Feb 6, 2026Locations: 12
Eligibility criteria

Participants or their legally acceptable representative must sign an ICF indicat... [+9]

Burkitt´s Leukemia according to World Health Organization (WHO) classification. [+29]

Read more
Status: Recruiting

A Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Preliminary Efficacy of YK012

This study aims to provide a basis for further clinical development of YK012.

Participants needed: 48
Trial details
Phase: Phase 1Age: 18-65Biological sex: AllType: InterventionalSponsor: Excyte Biopharma LtdUpdated: Feb 5, 2026Locations: 1
Eligibility criteria

Written informed consent obtained from the patient prior to performing any study... [+10]

History of malignancy other than B-cell NHL within 5 years prior to study entry,... [+12]

Read more
Status: Recruiting

Study of YK012 in Primary Membranous Nephropathy

The goal of this clinical trial is to evaluate the safety, tolerability, pharmacokinetics (PK), pharmacodynamics (PD), immunogenicity, and preliminary efficacy of YK012 in participants with primary membranous nephropathy (PMN).

Participants needed: 72
Trial details
Phase: Phase 1Age: 18-80Biological sex: AllType: InterventionalSponsor: Excyte Biopharma LtdUpdated: Nov 17, 2025Locations: 1
Eligibility criteria

Aged 18 to 80 years (inclusive), regardless of gender. [+6]

Diagnosis of secondary membranous nephropathy. [+16]

Read more